Thank you for downloading this publication. Please let us know why you chose this publication:
Why are you interested in this publication?
What organisation do you represent?
You will only need to complete this form once per browser/device
How do you prefer to read or receive publications?

We may contact you for feedback on the publication you have downloaded. If you do not want to be contacted, please leave the email field blank. Your information will never be shared with any third party.

Malaria Consortium US Donate
  • About us
    • Who we are
    • Our Strategy
    • Governance
    • Aid transparency
  • Projects
  • Where We Work
  • What we do
    • Diseases
    • Our responses
    • Burden reduction to elimination
    • Data-informed decision-making & digital approaches
    • Health sector resilience
    • Research & policy change
    • Networks & partnerships
  • News & Resources
    • News
    • Blog
    • Videos
    • Webinars
    • Photo stories
  • Publications
    • Interactive publications
  • Support us
  • Contact Us
    • Newsletter
  • Work with us
    • Tenders
  • Home
  • »
  • »
  • A hybrid effectiveness-implementation study protocol to assess the effectiveness and chemoprevention efficacy of implementing seasonal malaria chemoprevention in five districts in Karamoja region, Uganda
  • »
  • Videos

Publication Date:
30/01/2023

Type:
Journal article
Publication

A hybrid effectiveness-implementation study protocol to assess the effectiveness and chemoprevention efficacy of implementing seasonal malaria chemoprevention in five districts in Karamoja region, Uganda
Author(s): Kajubi R, Ainsworth J, Baker K, Richardson S, Bonnington C, Rassi C, Achan J, Magumba G, Rubahika D, Nabakooza J, Tibenderana J, Nuwa A, Opigo J

Publication Date:
30/01/2023
Type:
Journal article

Background

The World Health Organization (WHO) recommends seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine for children aged 3–59 months, living in areas where malaria transmission is highly seasonal. However, due to widespread prevalence of resistance markers, SMC has not been implemented at scale in East and Southern Africa. An initial study in Uganda showed that SMC with SPAQ was feasible, acceptable, and protective against malaria in eligible children in Karamoja region. Nonetheless, exploration of alternative regimens is warranted since parasite resistance threats persist.

Objective

The study aims to test the effectiveness of SMC with DP or SPAQ (DP-SMC & SPAQ-SMC), chemoprevention efficacy as well as the safety and tolerability of DP compared to that of SPAQ among 3–59 months old children in Karamoja region, an area of Uganda where malaria transmission is highly seasonal.

Methods

A Type II hybrid effectiveness-implementation study design consisting of four components: 1) A cluster randomised controlled trial (cRCT) using passive surveillance to establish confirmed malaria cases in children using both SPAQ and DP; 2a) A prospective cohort study to determine the chemoprevention efficacy of SPAQ and DP (if SPAQ or DP clears sub-patent  infection and provides 28 days of protection from new infection) and whether drug concentrations and/or resistance influence the ability to clear and prevent infection; 2b) A sub-study examining pharmacokinetics of DP in children between three to <6 months; 3) A resistance markers study in children 3–59 months in the research districts, plus the standard intervention districts to measure changes in resistance marker prevalence over time and finally; 4) A process evaluation.

Conclusion

This study will inform malaria policy in high-burden countries and contribute to progress in malaria control.

Published in Gates Open Research 

Click here to download

Country: Uganda

Keywords: Research | Malaria | Seasonal malaria chemoprevention | SDG3

 

 

« Back to Publications
Follow us on our social channels
  • Jobs
  • Contact us
  • Annual reviews
  • Support us
  • About us
  • Sitemap
  • Policies
  • Modern Slavery Statement
Fundraising Regulator logo
© 2023 Malaria Consortium | Charity No. 1099776 | Company No. 4785712